Finn
EXEL Biotechnology · Oncology · Commercial-stage · Thesis updated November 1, 2026

Cabo funds the next Exelixis bet

01 Running thesis

One big drug, one big follow-up

Exelixis is in a stronger spot than many biotech companies because it already makes real money. CABOMETYX, its brand name for cabozantinib, funds the company while it runs trials and buys back stock. The core business captures more than 50% new patient market share in second-line plus neuroendocrine tumors, known as NET.

The bull case is simple. Cabo is still growing in kidney cancer, expanding 11% year-over-year in the third quarter. The company also has a clear path to a second major franchise if the FDA approves zanzalintinib for colorectal cancer on March 3, 2027.

The bear case centers on the pace of growth and trial delays. The FDA pushed the zanzalintinib colorectal cancer decision from December 2026 to March 2027, and a key kidney cancer data readout slipped into the first quarter of 2027. Also, the NET indication is ramping slower than initially expected. Until zanzalintinib is approved and starts selling, Exelixis remains mostly a one-product story.

Finn considers the setup balanced. Exelixis has strong current performance and financial health, but the stock needs proof that the next drug can become a broad commercial success.

Oct 2026▼Management reported delays to key pipeline catalysts, pushing the zanzalintinib colorectal cancer PDUFA date to March 3, 2027, and the STELLAR-304 readout to Q1 2027.
Aug 2026▼Management lowered full-year revenue guidance by $50 million at the midpoint due to a slower commercial ramp in neuroendocrine tumors. A subgroup in the colorectal cancer trial also failed to meet statistical significance.
May 2026→The Q1 2026 10-Q confirmed the December 3, 2026 PDUFA date for zanzalintinib in colorectal cancer and listed no material risk-factor changes.
May 2026▼Management moved the STELLAR-304 readout to the second half of 2026. That delays a key proof point for zanzalintinib in kidney cancer.
Feb 2026▲The FDA accepted the zanzalintinib NDA in colorectal cancer. CABOMETYX also passed $100 million of U.S. cabo revenue from neuroendocrine tumors in 2025.
Nov 2025▲The NET launch was ahead of expectations, with management citing more than 40% new patient share in the oral second-line plus NET segment. Exelixis also prepared to file zanzalintinib for colorectal cancer.
Jul 2025▲Positive STELLAR-303 colorectal cancer data strengthened the zanzalintinib case. The update was tempered by the end of STELLAR-305 in head and neck cancer and a delay in STELLAR-304.
02 Business model

Cabo pays the bills

Exelixis makes most of its money by selling CABOMETYX in the United States. It also receives collaboration revenue, mainly royalties from Ipsen and Takeda, which sell cabozantinib outside the United States.

The business is heavily tied to U.S. cabo demand. In early 2026, net product revenue made up over 90% of total revenue. This means the company still depends heavily on domestic prescriptions.

The company uses this cash to fund cancer trials, especially zanzalintinib, and to support business development. This model works well when cabo keeps growing and trials hit. It breaks if payers cut net prices, doctors switch to rivals, or zanzalintinib fails to win broad approval.

03 Product portfolio

What Exelixis sells and tests

Cash cow

CABOMETYX in renal cell carcinoma

This is the core market for Exelixis. RCC is kidney cancer, and CABOMETYX is the number one prescribed targeted treatment there.

Growth engine

CABOMETYX in neuroendocrine tumors

The FDA approved CABOMETYX for pNET and epNET in 2025. The drug captures high new patient share, though the indolent nature of the disease slows the revenue ramp.

Growth engine

Zanzalintinib in colorectal cancer

This is the key next-drug bet. The FDA accepted the NDA for zanzalintinib plus atezolizumab, with a March 3, 2027 PDUFA decision date.

Option

Zanzalintinib in non-clear cell RCC

STELLAR-304 tests zanzalintinib plus nivolumab against sunitinib in untreated non-clear cell kidney cancer. Top-line results are expected in the first quarter of 2027.

Option

Early oncology pipeline

Exelixis is testing earlier drugs such as XL309, XB010, XB628, XB371, and newly nominated XL558. These could matter later, but they are not the main value driver today.

Steady

Partnered legacy products

COTELLIC and MINNEBRO came from Exelixis research and are marketed through partners. They add breadth, but cabo remains the main business.

04 Business segments

Revenue is still concentrated

Net product revenues91%modest
Collaboration revenues9%growing fast

Net product revenue makes up roughly 91% of total revenue, meaning Exelixis depends primarily on U.S. cabozantinib sales.

05 Risk factors

What could go wrong

Zanzalintinib delay and label risk

High impact · Medium odds

The FDA delayed the colorectal cancer decision to March 3, 2027. Additionally, the non-liver metastasis subgroup failed to hit statistical significance for overall survival. This introduces the risk of a narrower label than investors hope.

We watchFDA action on the March 3, 2027 PDUFA date and any wording on the approved patient group.

Cabo growth slows

High impact · Medium odds

Most revenue still comes from cabozantinib. The neuroendocrine tumor launch is ramping gradually due to patient kinetics. If kidney cancer share also weakens, growth will stall.

We watchQuarterly U.S. CABO franchise net product revenue and management comments on new patient starts.

STELLAR-304 data miss

High impact · Medium odds

STELLAR-304 is the next major zanzalintinib kidney cancer trial. A weak result in early 2027 would hurt the case that zanzalintinib can become a broad franchise.

We watchTop-line STELLAR-304 results in the first quarter of 2027.

Payer discounts pressure margins

Medium impact · Medium odds

Management expects 2026 gross-to-net deductions of approximately 30 percent. Gross-to-net is the gap between list price and what the company keeps after rebates and fees. A higher percentage means Exelixis keeps less of each sale.

We watchGross-to-net guidance and commentary on discounted channels.

Competition changes doctor habits

Medium impact · Medium odds

CABOMETYX competes with other targeted drugs and immune therapy combinations. It leads in renal cell carcinoma today, but doctors can change prescribing if rivals show better data or cleaner safety profiles.

We watchMarket share data in RCC and NET, plus new trial results from competing cancer drugs.
06 Quick answers

In one breath

How does Exelixis make money?

Exelixis mainly sells CABOMETYX in the United States. It also earns collaboration revenue, including royalties from Ipsen and Takeda for cabozantinib sales outside the United States.

What is the biggest upcoming Exelixis catalyst?

The biggest dated catalyst is the FDA decision for zanzalintinib in colorectal cancer on March 3, 2027. Investors will also watch STELLAR-304 data in non-clear cell kidney cancer in the first quarter of 2027.

Why does concentration risk matter for EXEL?

Most current revenue depends on cabozantinib. If CABOMETYX loses share, faces access pressure, or has a safety issue, Exelixis would feel it quickly because zanzalintinib is not yet a major seller.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 1, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Exelixis Q3 2026 earnings transcript
  2. Exelixis Q2 2026 earnings transcript
  3. Exelixis Q2 2026 Form 10-Q
08 Explore the industry

Comparable Biotechnology companies

Companies near Exelixis, Inc. in Finn's Biotechnology industry ranking.

Get started with Finn today